SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001839882-23-023291
Filing Date
2023-09-01
Accepted
2023-09-01 16:45:30
Documents
12
Period of Report
2023-08-30
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_083023.htm   iXBRL 8-K 38032
  Complete submission text file 0001839882-23-023291.txt   213861

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE admp-20230830.xsd EX-101.SCH 3054
3 XBRL LABEL FILE admp-20230830_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE admp-20230830_pre.xml EX-101.PRE 22385
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_083023_htm.xml XML 3312
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 231233143
SIC: 2834 Pharmaceutical Preparations